T he complex nat ure of the schistosome parasite and its interaction with the mammalian host necessitates the continued use of live intact anim al models in schistosomiasis research. T his review acknowledges this necessity and highlights some of the important insights into the pathogenesis of the disease that have been gained from using various animal models. T he use of non-human primates as more relevant models of human schistosomiasis is stated. In addition, the importance of animal welfare consideration when using primat es for research is emphasized. Finally, some guidelines for the refined capture, handling and early humane endpoints for non-human primat es to be used in experimental schistosomiasis are suggested.
Schistosomiasis is a chronic debilit at ing parasitic infection of man and other mammalian species that is caused by the digenetic trematodes of the genus Sc h isto so m a . T here are more than 16 identi®ed species of Sch isto so m a that may potentially infect humans, but only ®ve cause signi®cant morbidity nam ely S. h a e m a to b iu m , S. ja po nic um , S. m e k o ngi , S. inte rc a la tu m and S. m a nso ni.
Schistosomiasis is the most widespread water-borne parasitic disease and is endemic in 74 countries, mainly in the tropics and subtropics. It is estim ated that about 600 million people are at risk of infection, with over 200 million already being infected (WHO 1996 ) . In addition to mortality, the disease can severely impair the growth and development of children, and signi®cantly reduce the working capacity of adult s as well as interfere with reproductive health, thus emphasizing the socioeconomic im portance of the disease.
T he pathological hallm ark of schistosomiasis is the anti-egg granulomatous response in the host tissues. In the baboon the anti-egg responses are restricted to the liver and intestines, hence the disease is essentially hepato-intestinal . Two discrete phases of the disease have been described. T he ®rst phase is characterized by a vigorous granulomatous response and overt clinical signs. T he second is the chronic phase of the disease, whereby there is resolution of the granulomas and amelioration of the hepato-intestinal disease.
Schistosomiasis control methods and strategies
snail host, chemotherapy, health educat ion and good sanitation, i.e. functional sewerage or provision of pit latri nes and clean tap water. Often a combinat ion of these methods has to be adopted to make any signi®cant reduction in transmission (WHO 1993 ) .
Chemotherapy is by far the most successful method used in the control of schistosomiasis, essentially because of the availabil ity of safe and ef®cacious drugs such as praziquantel (Cioli 1998 ) . T he use of mass chemotherapy has considerably reduced the morbidity of schistosomiasis in many endemic countries (WHO 1993) . Inherent drawbac ks with the use of chemotherapy include the potential for the emergence of drugresistant schistosome strains (Stelma e t a l. 1995) and the fact that cured individual s are fully susceptible to a new infection.
T he ultimate strategy in the control of schistosomiasis is the development of a vaccine (Wilson & Coulson 1998 ) . T he fact that there is partial protection following a natural schistosome infection implies that vaccine development is both rat ional and feasible (Bergquist & Colley 1998 ) . Radiationattenuated cercariae vaccine consistently confers high protection in both rodents and non-human primates (Coulson 1997) . However it is neither practical nor ethical to use irradiat ion-attenuated organisms as a vaccine in humans, but it has served to increase the knowledge of mechanisms of protection in animal models (Wilson & Coulson 1998 ).
The need for animal models
Despite remarkable advanc es in the understanding of the basic biology of schistosomes and the disease they cause, the control and eventual eradication of schistosomiasis has proved intract able. T his is because of the complex nature of schistosomes and their even more complex interaction with the vertebrate host. Schistosomes have evolved spectac ular mechanisms not only for evading the deleterious host immune response (Ogilvie & Wilson 1976 ) but also for exploiting these same responses for selfperpetuation (Doenhoff e t a l. 1986). T he net effect of this is that schistosomes are long-lived parasites and the infections tend to be chronic and debilit at ing rather than acute and fatal.
In addition to the evasive nature of the schistosome parasite, there are a number of enigmatic phenomena associated with the biology of schistosomiasis. First, adult schistosome worms inhabit the blood stream , which is a hostile im munological niche. Survival is ensured by the abi lity of schistosomes to acquire host antigens, an im mune evasion mechanism referred to as antigenic disguise. Secondly, the schistosome egg elicits an im mune-mediated in¯ammatory response that not only protects the host tissues but also aids in the parasite's passage through the tissues (Doenhoff e t a l. 1986). T hirdly, schistosomes are antigenically complex multi-stage parasites, with each stage occupying a different anatom ical site within the host and expressing differing antigenicity. T hus, different immunological responses, which may at times be antagonistic, may be required to eliminate each of the life stages. For example, a T h2-associated im mune response with high interleukin (IL)-4, IL-5 in humans (Medhat e t a l. 1998 ) and IgE expression in humans (Dunne e t a l. 1997 ) and baboons (Nyindo e t a l. 1999 ) is required for the elimination of schistosomula and adult parasites, yet a T h1 response with elevated interferon (IFN )-g, is ideal for ameliorating the schistosome egg granuloma in mice . To make any meaningful study of these differing but intricately inter-relat ed mechanisms, some of which have confounding effects on each other, inevitabl y requires the use of live animals.
Although the ultimate aim is to eradicate the schistosome parasite from the human population, a more realistic goal is reduction of the morbidit y and mortality in endemic populations. Since adult schistosome worms do not replicate in the mammalian host, any intervention that will prevent the development of the parasite into the adult stage will suf®ce. Indeed some research groups argue that sterile im munity in schistosomiasis may not even be desirable. T he effectiveness of such interventions, be they therapeutic or vaccine-based, is dependent upon the infection of experimental anim als with a known number of cercariae. T he infected anim als are then perfused after 5±6 weeks to recover the adult worms and the protection level calculated by comparing the mean number of adult worms recovered from vaccinated or treated animals with that from non-vac cinated or non-treated anim als. As further supportive evidence of a reduction in morbidity, tissue lesions such as granulomat a density and diam eter have been assessed.
Rodent models
A variety of anim al models have been used to study the basic biology, immunology and pathogenesis of schistosomiasis. Rodents, and particularly inbred mice, have tended to be the animals of choice, essentially because of their easy availabilit y, fecundity and susceptibility to experimental infection. Because of the availabilit y of a variety of mutant and genetically manipulated strains, mice have been particularly invaluable in the study of the mechanisms of granulomatous in¯ammation and its modulati on (Boros & Whit®eld 1999) . Subsequently, most of the knowledge on schistosomiasis im munity, particularly regarding the contribut ion of the T h1 and T h2 arms of the immune system to pathology and protection, has been obtained from murine studies.
In S. m a nso ni infected mice, T h1 type cytokines, IFN-g and IL-2 responses, predominate prior to egg laying (Wynn e t a l. 1993). T his is followed by a dramatic increase in T h2 cytokines (IL-4, IL-5 and IL-10 ) coincident with peak granuloma formation (Gryzc h e t a l. 1991). T he balanc e between T h1 and T h2 cytokine expression determines the extent of granulomatous in¯ammat ion, with large granulomata being associated with strong T h2 responses, and minimal lesions with dom inant T hl cytokines .
T he overall contribution of T h1 and T h2 associated immune responses is best illustrated by studies utilizing the signal transducer and activator of transcription in (Stat-) 4 and Stat-6 knock-out mice, which have defects in the signal transduction path-ways that affec t T h1 and T h2 cells, respectively . While Stat-6 de®cient mice developed remarkably decreased pulmonary and hepatic granulomata and collagen deposition, the Stat -4 de®cient mice had only a marginal reduction in granulomata, con®rming the role of T h2 cells in granuloma development (Kaplan e t a l. 1998 ).
T he rat is a non-permissive host for schistosom iasis but has nevertheless been studied extensively as it provides an immunological paradigm for successful parasite rejection (Capron 1998 ). Schistosomes do not reach sexual maturity in the rat, being spontaneously eliminated in the third week following infection. T his schistosome attri tion is im mune-mediated and the antibody dependent cell-mediated cytotoxicity mechanism plays a major role (Capron & Capron 1994 ) . Parasite elimination in the rat coincides with eosinophilia, elevated IgE in circulation and mast cell degranulati on (Cutts & Wilson 1997 ) . Furtherm ore, passive transfer experiments using monoclonal IgE antibody have con®rmed in vivo the ef®cacy of IgE in this protection (Verwaerde e t a l. 1987 ).
Non-human primate models
T he murine model has several serious limitations. First, because of its size and lifespan it is virtual ly impossible to reproduce the low infection rat es for prolonged periods of time characteristic of human infections in the mouse. Even one worm pair in a mouse leads to a tissue egg burden far greater than a heavily-infected human (Dunne & Pearce 1999 ) . Secondly mice are not suitabl e models for chemotherapy and re-infection experiments because of the development of severe pathology leading to portocaval shunting (Wilson 1990 ). Finally, extrapolat ion of data from mice to humans is not without problems (Fal lon 2000 ) as obvious anat omical, genetical and im munological differences exist between the two species. In view of this, it has become necessary to develop nonhuman primate models for schistosmiasis.
T he chimpanzee is susceptible to both experimental and natural schistosome infection and develops clay-pipe-stem ®brosis of the liver (Sadun e t a l. 1970 ) during a primary schistosome infection. T he cercarial dose, mode of exposure and the fecundity of the fem ale worms are some of the parasite factors that have been associated with a risk of hepatic ®brosis. For example, chimpanzees exposed to 2500 but not those exposed to 250 S. m a nso ni cercariae developed pipe-stem ®brosis (Sadun e t a l. 1970 ) . In additi on, the occurrence of spontaneous hepatocellular carcinoma related to an S. m a nso ni infection has been reported (Abe e t a l. 1993 ). It is thus fair to state that the chimpanzee is probably the most ideal model for the study of schistosomiasis. However, it is becoming increasingly dif®cult to carry out biomedical research on chimpanzees because of ethical considerations. Currently, most ethics committees do not allow experiments with chimpanzees whose ultim at e endpoint is death. In this respect, the chimpanzee ceases to be an available model since perfusion to recover adult worms is an integral component of current or present schistosomiasis research, particularly when evaluat ing the ef®cacy of a potential vaccine or chemotherapeutic agent.
T he baboon is the most frequently-used non-human primate in schistosomiasis research because of a multiplicity of qualities that make them more relevant models than rodents . Baboons maintain natural infections in the wild (Fenwick 1969 ) and are highly susceptible to experimental infections (Farah e t a l. 1997 ). T hey develop hepatic and intestinal lesions during the acute phase, modulate these lesions in the chronic phase of the disease and acquire protective im munity (Farah & Nyindo 1996 , Farah e t a l. l997, Mola e t a l. 1999, Nyindo e t a l. 1999). Unlike the mouse, there is a simultaneous T h1 and T h2 response at the peak egg deposition period in the baboon, followed by a decline in both responses from the onset of modulation.
Baboons acquire immunity on vaccination. For example, immunization with irradiated cercariae stimulates over 50 % protection (Yole e t a l. 1996) which is associated with elevated serum levels of schistosome-speci®c IgG and IgE. In addition, vaccination with irradiated cercariae results in reduction of the intestinal pathology (Farah & Nyindo 1996) . Some protection to challenge infection following vaccination with recombinant antigens has also been reported in baboons (Soisson e t a l. 1993) . T he moderate size, possibility of repeated sampling, and ease of perfusion for recovery of adult worms makes the baboon a good model for vaccine ef®cacy studies.
Baboons can sustain repeated schistosome infections without any untoward lesions such as portal-c aval shunting (Sturrock e t a l. 1984 ) and with subsequent development of acquired im munity and increased resistance to reinfection. Such re-infection episodes are characterized by reduced adult worm burden and granulomat ous in¯ammation (Mola e t a l. 1999 ) which, as in humans, are associated with high serum levels of parasit e-speci®c IgE (Nyindo e t a l. 1999 ). In addition, as with humans (Fulford e t a l. 1998 ), there is an agedependent susceptibility to infection in wild baboons (Mull er-Graf e t a l. 1997 ). Hepatic ®brosis invariably occurs in primary murine schistosomiasis mansoni but not in baboons. Secondary infections following chemotherapy may, however, lead to hepatic ®brosis in baboons (Farah e t a l. 2000 ) . In contrast to the mouse where ®brosis is primarily peri-ovular, baboon ®brosis is peri-portal and is neither associat ed with granulomata density and size nor intensity of infection but the frequency of cercarial exposures (Farah e t a l. 2000) .
Constraints lim iting the use of baboons in schistosomiasis research include the high costs involved in trapping and maintaining monkeys in captivity. T here may also be variation in data obtai ned from wild-caught baboons due to their heterogeneous genetic backgroun d. In addition, some speci®c im munological reagents suitable for baboon work may not be currently available.
Animal welfare aspects of using non-human primates
Having justi®ed the necessity of utilizing live intact monkeys for in vi vo studies in schistosomiasis research, it is crucial to consider how these animals should be acquired and handled during experimentation. Because of the phylogenetic closeness of non-human primates to man, the use of these anim als is quite naturally subject to close scrutiny. Consequently, although the number of non-human primates used in biomedical research is minuscule when compared with other species, this particular use attrac ts signi®cant interest and severe criticism (Ball s 1995 ). T he Directorate-General XII of the EU acknowledges that primates have to be used in certain research projects and for the testing of some products. T his in no way contradicts its two main objectives: to reduce the numbers of primat es im ported into the EU for research and to seek alternati ve methods, which can replace the use of primates in research. T his has resulted in the setting up of the European Primat e Resource Network (EUPREN ) and the Primate Vaccine Evaluation Network (PVEN ). One of the objectives of EUPREN is to ensure the controlled and ethical use of primates in research. To achieve this, it envisages increasing the breeding of research primates within the EU and concentrating primat e research in specialist breeding = research centres. PVEN was set up in the belief that the unnecessary transport of primates from source countries should be avoided by the development of research facil ities in the source countries themselves.
With regard to optim izing anim al welfare, a strong case can be built for using primates captured in the wild for primat e research in the source countries. Locating research to these countries renders it possible to accurately capture the number of anim als necessary for individual projects eliminating the dif® culty often encountered in Europe, for example, of matc hing supply and dem and. In addition, the animals captured in the wild in Kenya, for example, can be group-housed in an environment that is much more similar to the anim als' natural environment than what is possible in Europe. In Kenya the animals can be group-housed in suitabl e social groups in their natural environment and they can be fed their normal preferred diet. T his allows for husbandry conditions associated with minimal stress, and animals need only be con®ned to captivity during the acclim ati zation period and during the actual experiment, after which they can be euthanased.
It is a frequent misconception that all nonhuman primate species are endangered species threatened by extinction. On the contrary many species are not threatened, and several are regarded as pest animals in the source countries. In these countries (e.g. Kenya) non-human primat es like baboons and vervet monkeys are valuable assets and research programmes are focusing on making capture and early housing as stress-free for the anim als as possible (Suleman 1998 ) . It should be emphasized that all endangered species are bred in captivity.
When using animals in research the scientists have a moral and often legal obligation to minimize associat ed suffering. T he iden-ti® cation and implementation of early endpoints used in a research project is a practical application of`re®nement' as envisaged by Russell and Burch (1959 ) . It is imperative that a combination of behavioural, clinical, physiological and project speci®c measures are used in order to allow the early euthanasia of animals as soon as the desired effect has been reached or if negative side effects become prominent. Recognition of the abnormal state depends on an awareness of and familiarit y with the normative biology and behaviour of the species in question. It is hence im perative that experienced and competent staff be used in animal experimentat ion, allowing proper im plementati on once appropriat e endpoints have been de®ned (Hau 1998 ) .
With regard to experimental S. m a nso ni infection of the baboon , the following re®ned guidelines and humane endpoints are suggested.
( Cercarie should preferably be given in multiple small doses. T his has the dual advantage of resulting in reduced morbidity as compared with an equivalent single-dose infection, as well as of mim icking the natural human exposure. (4 ) Anim a l h a nd ling a nd sa m plin g:
Recommended sampling intervals for collection of blood for serum or cells should be 2 weeks. If invasive procedures such as collection of liver biopsies are necessary then this should be done once every 4 weeks. (5 ) Mo nito ring infe c te d a nim a ls: Animals must be visually examined daily within their cages for demeanor, body condition and evidence of diarrhoea and dysentery. Any suspected cases of ill health must be put in isolation cages or anaesthetized, if necessary, for closer examination. (6 ) Expe rim e nta l e nd po ints : Most anim als will remain clinically unaffected by the infection, and euthanased according to the experimental protocol. However a proportion of the anim als show disturbed behaviour or clinical disease symptoms. In these cases suggested criteria for term ination are: (a) Severe dysentery (blood in the stool) and abdom inal cramps that are unresponsive to anti-bacteri al treat ment and persist for more than 5 days; or (b) Persistent anorexia coupled with more than 10 % body weight loss. (7 ) Euth a na sia : T he recommended method for euthanazing baboons is by intravenous injection of an overdose of barbi-turates such as 20 % pentobarbit one sodium .
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